Stifel Nicolaus Forecasts Strong Price Appreciation for Medtronic (NYSE:MDT) Stock

Key Points

• Stifel Nicolaus raised its price target for Medtronic (NYSE:MDT) from $90.00 to $105.00, indicating an expected upside of 8.45% from its previous close, while maintaining a "hold" rating.
• Despite the positive outlook from some analysts, Goldman Sachs has set a sell rating with a price target lowered to $81.00, while other firms have increased their price targets, with Argus targeting $115.00.
• Medtronic recently reported earnings per share of $1.26, exceeding expectations, and set a FY 2026 guidance of 5.600-5.660 EPS.

Medtronic (NYSE:MDT - Get Free Report) had its price objective lifted by stock analysts at Stifel Nicolaus from $90.00 to $105.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a "hold" rating on the medical technology company's stock. Stifel Nicolaus' price objective suggests a potential upside of 8.45% from the company's previous close.

MDT has been the topic of a number of other reports. The Goldman Sachs Group dropped their price target on Medtronic from $82.00 to $81.00 and set a "sell" rating on the stock in a research report on Wednesday, October 1st. Wolfe Research raised Medtronic from an "underperform" rating to a "peer perform" rating in a research report on Monday, June 30th. Daiwa Capital Markets boosted their price target on Medtronic from $101.00 to $104.00 and gave the stock a "buy" rating in a research report on Friday, September 12th. UBS Group boosted their price target on Medtronic from $94.00 to $95.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 20th. Finally, Argus boosted their price target on Medtronic from $105.00 to $115.00 and gave the stock a "buy" rating in a research report on Tuesday, August 26th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Medtronic has an average rating of "Moderate Buy" and an average price target of $101.82.

Medtronic Stock Down 1.1%

Shares of MDT stock traded down $1.05 during midday trading on Thursday, reaching $96.82. 1,415,479 shares of the stock were exchanged, compared to its average volume of 7,597,098. Medtronic has a 1 year low of $79.29 and a 1 year high of $99.37. The company's 50 day moving average is $93.31 and its two-hundred day moving average is $88.65. The company has a current ratio of 2.01, a quick ratio of 1.50 and a debt-to-equity ratio of 0.54. The firm has a market cap of $124.19 billion, a PE ratio of 26.68, a price-to-earnings-growth ratio of 2.59 and a beta of 0.78.

Medtronic (NYSE:MDT - Get Free Report) last posted its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping analysts' consensus estimates of $1.23 by $0.03. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The firm had revenue of $8.58 billion for the quarter, compared to the consensus estimate of $8.37 billion. During the same quarter in the prior year, the business earned $1.23 EPS. The business's revenue for the quarter was up 7.7% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. On average, equities research analysts predict that Medtronic will post 5.46 EPS for the current year.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the transaction, the executive vice president directly owned 35,615 shares of the company's stock, valued at $3,261,621.70. This represents a 19.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director William R. Jellison purchased 2,500 shares of the stock in a transaction dated Monday, August 25th. The shares were purchased at an average cost of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the acquisition, the director directly owned 5,000 shares in the company, valued at approximately $461,850. This trade represents a 100.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.26% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Medtronic

Hedge funds and other institutional investors have recently modified their holdings of the stock. 1248 Management LLC purchased a new stake in shares of Medtronic in the 1st quarter worth $26,000. Delos Wealth Advisors LLC purchased a new stake in shares of Medtronic in the 2nd quarter worth $27,000. Columbia River Financial Group LLC purchased a new stake in shares of Medtronic in the 1st quarter worth $28,000. Twin Tree Management LP purchased a new stake in shares of Medtronic in the 1st quarter worth $29,000. Finally, Activest Wealth Management increased its stake in shares of Medtronic by 3,577.8% in the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company's stock worth $30,000 after purchasing an additional 322 shares in the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.